Literature DB >> 23975028

Identification and characterization of psoralen and isopsoralen as potent CYP1A2 reversible and time-dependent inhibitors in human and rat preclinical studies.

Xiao-Mei Zhuang1, Yu-Huan Zhong, Wei-Bin Xiao, Hua Li, Chuang Lu.   

Abstract

Naturally occurring furanocoumarin compounds psoralen (PRN) and isopsoralen (IPRN) are bioactive constituents found in herbaceous plants. They are widely used as active ingredients in several Chinese herbal medicines. In this study, the CYP1A2 inhibitory potential of PRN and IPRN was investigated in rats in vitro and in vivo as well as in human liver microsomes. Both compounds exhibited reversible and time-dependent inhibition toward rat microsomal cyp1a2. The IC(50), k(inact), and K(I) values were 10.4 ± 1.4 μM, 0.060 ± 0.002 min(-1), and 1.13 ± 0.12 μM for PRN, and 7.1 ± 0.6 μM, 0.10 ± 0.01 min(-1), and 1.95 ± 0.31 μM for IPRN, respectively. In human liver microsomal incubations, potent reversible CYP1A2 inhibition was observed for both compounds, with IC(50) values of 0.26 ± 0.01 μM and 0.22 ± 0.03 μM for PRN and IPRN, respectively. However, time-dependent inhibition was only observed for IPRN, with kinact and KI values of 0.050 ± 0.002 min(-1) and 0.40 ± 0.06 μM, respectively. Coadministration with PRN or IPRN significantly inhibited cyp1a2 activity in rats, with the area under the curve (AUC) of phenacetin increasing more than 5-fold. Simcyp simulation predicted that PRN would cause 1.71- and 2.12-fold increases in the phenacetin AUC in healthy volunteers and smokers, respectively. IPRN, on the other hand, would result in 3.24- and 5.01-fold increases in phenacetin AUCs in healthy volunteers and smokers, respectively. These findings represent the first detailed report comparing the potential drug-drug interactions of PRN and IPRN, and provide useful information for balancing safe and efficacious doses of PRN and IPRN.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23975028     DOI: 10.1124/dmd.113.053199

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Effects of MicroRNA-34a on the Pharmacokinetics of Cytochrome P450 Probe Drugs in Mice.

Authors:  Joseph L Jilek; Ye Tian; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2017-03-02       Impact factor: 3.922

2.  Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy via screening of a natural product repository.

Authors:  Prashant Joshi; Vinay R Sonawane; Ibidapo S Williams; Glen J P McCann; Linda Gatchie; Rajni Sharma; Naresh Satti; Bhabatosh Chaudhuri; Sandip B Bharate
Journal:  Medchemcomm       Date:  2018-01-08       Impact factor: 3.597

3.  Dibenzyl trisulfide binds to and competitively inhibits the cytochrome P450 1A1 active site without impacting the expression of the aryl hydrocarbon receptor.

Authors:  Shaniece Wauchope; Monika A Roy; William Irvine; Isaac Morrison; Eileen Brantley; Maxine Gossell-Williams; Alicia R Timme-Laragy; Rupika Delgoda
Journal:  Toxicol Appl Pharmacol       Date:  2021-03-24       Impact factor: 4.219

Review 4.  PBPK modeling and simulation in drug research and development.

Authors:  Xiaomei Zhuang; Chuang Lu
Journal:  Acta Pharm Sin B       Date:  2016-06-23       Impact factor: 11.413

5.  Isopsoralen Enhanced Osteogenesis by Targeting AhR/ERα.

Authors:  Luna Ge; Yazhou Cui; Kai Cheng; Jinxiang Han
Journal:  Molecules       Date:  2018-10-11       Impact factor: 4.411

6.  Comparison of the Inhibitory Potential of Bavachalcone and Corylin against UDP-Glucuronosyltransferases.

Authors:  Lina Shan; Shuman Yang; Gang Zhang; Dun Zhou; Zhenyu Qiu; Lei Tian; Hongxia Yuan; Yujun Feng; Xianbao Shi
Journal:  Evid Based Complement Alternat Med       Date:  2014-04-16       Impact factor: 2.629

7.  Selective Inhibition of Bakuchicin Isolated from Psoralea corylifolia on CYP1A in Human Liver Microsomes.

Authors:  Sun Joo Kim; Heung Chan Oh; Youn-Chul Kim; Gil-Saeng Jeong; Sangkyu Lee
Journal:  Evid Based Complement Alternat Med       Date:  2016-02-09       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.